2030
Collegium Pharmaceutical, Inc.·Products & Services·4 segments·Rolls up to Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)
| Segment | Q4 '24 | Q4 '25 |
|---|---|---|
| Jornay PM | $83.83M | $83.83M |
| Symproic and other | — | $7.29M |
| Belbuca | — | $0 |
| Total | — | — |